Gilead Sciences (NASDAQ:GILD) announced Friday that its antibody-drug conjugate Trodelvy reached the main goal compared to ...

Gilead (GILD) announced topline results from the Phase 3 ASCENT-03 study of Trodelvy. The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful ...

After meeting the mark alongside Keytruda in PD-L1-positive breast cancer earlier this year, Gilead Sciences' antibody-drug ...

Gilead Sciences (NasdaqGS:GILD) recently announced positive results from its ASCENT-03 study, leading to a significant role ...

Gilead's Trodelvy shows significant improvement in progression-free survival for metastatic triple-negative breast cancer ...

Trodelvy’s combination with Merck & Co.’s Keytruda was better than Keytruda and chemotherapy at prolonging the time before cancer returns or death in patients with previously untreated ...

Gilead Sciences, Inc. (GILD) announced on Monday that its late-stage study showed a combination of its drug Trodelvy with Merck's (MRK) immuno-oncology agent Keytruda significantly improved ...

Trodelvy (sacituzumab govitecan-hziy) is a prescription drug used to treat certain kinds of breast cancer. This drug can interact with some other medications. For example, Trodelvy can interact ...

The results of Gilead's much-anticipated TROPiCS-02 study of Trodelvy are in, and while the company says top-line data are positive, its guarded stance has rung some alarm bells.

Trodelvy + Keytruda improved progression-free survival over chemo + Keytruda in PD-L1+ metastatic TNBC. No new safety signals reported in ASCENT-04; overall survival trends will be tracked with mo ...